Impact of 4D-CT MIP reconstruction method on iGTV definition: A clinical case report.

J Appl Clin Med PhysSep 18, 2026
Case ReportRadiology (Diagnostic)Oncology (Medical)

Suhong Yu, Itai Pashtan

✦ AI-curated · Sources linked

Case in brief

A case during thoracic radiation therapy planning revealed a discrepancy in tumor extent due to the use of a phase-sorted 4D-CT maximum intensity projection (MIP) dataset, which truncated the inferior tumor boundary. A comparison with a cine-based MIP showed that the latter provided a more accurate representation of the tumor's motion envelope. This finding emphasized the need for thorough verification of MIP reconstruction methods in clinical practice.

Diagnostic / clinical pearl

Clinicians should verify the MIP reconstruction method used in 4D-CT imaging, as discrepancies can significantly affect internal gross tumor volume (iGTV) definition, especially in patients with irregular breathing patterns.

Why it matters

This case underscores the necessity for comprehensive quality assurance in motion management workflows to ensure accurate tumor delineation and effective treatment planning.

Source

PubMed · PMID 42754512

Published in J Appl Clin Med Phys. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Radiology (Diagnostic)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.